From annoyance to disruption: Suffering with hiccups that won t go away pressherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressherald.com Daily Mail and Mail on Sunday newspapers.
It s still chilly out, but the spring planting season is just.
It’s still chilly out, but the spring planting season is just around the corner. What are you adding to your garden when the weather starts to warm up?
Thank
2022 GUBERNATORIAL CANDIDATE RTC UNITY TOUR
Susan Patricelli Regan, CT Republican candidate for Governor 2022 has been meeting with RTC s in the NE with a continued expanding State visits scheduled to inform them of her campaign and to encourage a unified message to the party in activities for elections going forward in Connecticut.
Pictured is Susan with newly elected Vice Chair of the CT Republican Party, Mary Ann Turner at the April 1st Enfield RTC monthly meeting where Susan presented to an enthusiastic crowd of about 45 members.
AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator
Study to Examine Safety of SP-420 in MDS and MF
News provided by
Share this article
Share this article
BOSTON, Feb. 23, 2021 /PRNewswire/ AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). The opening of this trial in MDS and MF marks another critical step forward on the development path for SP-420, said AbFero CEO Thomas X. Neenan. Following the recently awarded Parkinson s research grants from EUREKA Eurostars and Cure Parkinson s, this trial is an additional building block in our strategy of developing safe chelators for both hematological indications and diseases of aging where iron is implicated.